New way to kill cancer found using body’s immune system

21 Jul 2009

Scientists have discovered a new way of killing cancer cells in a breakthrough that could eventually lead to new treatments for a range of different cancers.

Researchers at The University of Manchester, working with colleagues at the University of Southampton, investigated how antibody treatments make cancer cells kill themselves and found a previously undiscovered mechanism that could, in future, be even more effective in causing their death.

When antibodies bind to cells, including cancer cells, they can ‘flag’ those targets for destruction by the body’s immune system but this latest study has shown that antibodies can kill cancer cells directly. When the antibody binds, it causes lysosomes – small acid-containing sacs – inside the cell to swell and burst, rapidly releasing their toxic contents with fatal results for the cancer cell.

The study, published in the Journal of Clinical Investigation, offers hope of more alternative approaches to killing cancer cells that may have become resistant to the traditional chemotherapy treatments.

”A number of antibody treatments for cancer have been developed over the last decade and some of them are a huge step forward in treatment,” said Professor Tim Illidge, in Manchester’s School of Cancer and Imaging Sciences at the Paterson Institute for Cancer Research.

“Our research focused on several antibodies that bind to a molecule found on many leukaemia and lymphoma cells called CD20. Until now scientists did not understand exactly how these antibodies work as treatments for these blood cancers but our research not only identifies how they kill the cancer cells but also provides exciting insights into how other antibodies that use this mechanism might be developed.”

Dr Mark Cragg, from the University of Southampton, added: “Our findings are significant and open up the possibility of applying the knowledge of how antibodies can be developed to trigger cell death and may enable us to design treatments for other cancers.”

The large study was funded by the Association for International Cancer Research (AICR), Leukaemia Research, Cancer Research UK and Tenovus. Dr Mark Matfield of AICR, said: “The discovery of a new mechanism by which cancer cells kill themselves is an important step forward in cancer research. Killing the cancer cells is the basis of all successful cancer treatments.”

Dr David Grant, of Leukaemia Research, said: "The discovery of the unique pathway used by antibody therapies to kill cancer cells has, for the first time, revealed why they are more effective than chemotherapy. This may lead to new treatments for patients with blood cancers who cannot be cured using conventional chemotherapy.”

Dr Lesley Walker, Cancer Research UK’s Director of Cancer Information, said: “Although it’s at an early stage, this research provides valuable clues as to how monoclonal antibodies kill cancer cells, and could lead to more effective treatments for cancer in the future.”

Dr Ian Lewis, Research Manager of Tenovus, added: “The beauty of this research is that it shows how the body’s own immune system can be mobilised to selectively destroy a patient’s own cancer. Normally the immune system struggles to tell the difference between a cancer cell and a healthy cell, but thanks to this research we now know how successful antibody treatments work and therefore how to apply it to the whole area of antibody therapy for cancer.”

Ends

Notes for editors

AICR
AICR, the Association for International Cancer Research, is the leading cancer charity that funds research anywhere in the world. The charity awards grants to promising and prominent scientists to improve prevention, detection and treatment of the disease. The organisation is based in St Andrews, Scotland, but has international reach. Currently AICR is funding 233 projects in 24 countries.

Leukaemia Research
Leukaemia Research is the only national charity devoted exclusively to improving treatments, finding cures and learning how to prevent leukaemia, Hodgkin’s and other lymphomas, myeloma and the other related blood disorders, diagnosed in 24,500 people in the UK every year.

Cancer Research UK
Cancer Research UK is the world’s leading charity dedicated to beating cancer through research. The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has saved millions of lives. This work is funded entirely by the public. Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last thirty years. Cancer Research UK supports research into all aspects of cancer through the work of more than 4,500 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.

Tenovus
For more than 40 years, Tenovus has funded world class cancer research across the UK. Today, Tenovus funds a wide range of scientific and psychosocial research projects, and a package of emotional and practical support that covers the whole patient journey.

The University of Manchester
The University of Manchester is Britain's largest single-site university with a proud history of achievement and an ambitious agenda for the future. It is a member of the Russell Group and was ranked with the elite group of research universities traditionally formed by the triangle of Oxford, Cambridge and London in the recent Research Assessment Exercise 2008. Its external research income is £263 million.

The University of Southampton
The University of Southampton is a leading UK teaching and research institution with a global reputation for leading-edge research and scholarship across a wide range of subjects in engineering, science, social sciences, health and humanities.

For further information contact:

Aeron Haworth
Media Relations
Faculty of Medical and Human Sciences
The University of Manchester

Tel: 0161 275 8383
Mob: 07717 881563
Email: aeron.haworth@manchester.ac.uk